Evaluation of Sarcopenia with F-18 FDG PET/CT and relation with disease outcomes in patients with multiple myeloma

Basit Öğe Kaydı
dc.authoridGökyer, Ali/0000-0002-1653-6155
dc.authoridKorkmaz, Ulku/0000-0002-7155-7610
dc.authoridKirkizlar, Onur/0000-0001-7523-8599
dc.authoridBaysal, Mehmet/0000-0001-7681-4623
dc.authoridUmit, Elif/0000-0001-5589-3000
dc.authoridDemirci, Ufuk/0000-0001-6923-1470
dc.authoridReis, AlessanRSS/0000-0001-8486-7469
dc.authorwosidGökyer, Ali/AAQ-5700-2020
dc.authorwosidKorkmaz, Ulku/AAJ-4430-2020
dc.authorwosidKirkizlar, Onur/W-9594-2018
dc.authorwosidBaysal, Mehmet/E-9111-2018
dc.contributor.authorUmit, Elif G.
dc.contributor.authorKorkmaz, Ulku
dc.contributor.authorBaysal, Mehmet
dc.contributor.authorKaraman Gulsaran, Sedanur
dc.contributor.authorBas, Volkan
dc.contributor.authorDemirci, Ufuk
dc.contributor.authorOnur Kirkizlar, Hakki
dc.date.accessioned2024-06-12T11:01:49Z
dc.date.available2024-06-12T11:01:49Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction Multiple myeloma (MM) is a potentially incurable haematological malignancy with devastating manifestations including lytic bone lesions leading to fractures and renal insufficiency. As a disease of patients with a mean age of 66 years, both the disease and the continuous efforts of treatments lead to frailty and devastation. From this stand point, we aimed to evaluate the development of muscle loss in MM patients and also with a new method of sarcopenia evaluation, F-18 FDG PET/CT. While used for bone disease routinely, this method brings a fresh perspective of metabolic quantitation of alteration of muscles which may be regarded as muscle quality. Materials and Methods Data and images of 105 patients with MM both before and after treatment were evaluated in a retrospective manner. Results Both female and male patients were observed to be effected after MM treatment in terms of lumbar and femoral muscle evaluations with CT. Metabolic evaluations confirmed a loss of quality in muscles in terms of metabolic volume and total lesion glycolysis. Conclusion Sarcopenia should be evaluated in every patient and regarded as a treatment target. FDG PET/CT is an easy and handy tool to assess muscle mass and quality as well as MM disease status.en_US
dc.identifier.doi10.1111/ecc.13318
dc.identifier.issn0961-5423
dc.identifier.issn1365-2354
dc.identifier.issue6en_US
dc.identifier.pmid32888349en_US
dc.identifier.scopus2-s2.0-85090133772en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1111/ecc.13318
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21039
dc.identifier.volume29en_US
dc.identifier.wosWOS:000566363100001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofEuropean Journal Of Cancer Careen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectFDG PETen_US
dc.subjectCTen_US
dc.subjectMultiple Myelomaen_US
dc.subjectSarcopeniaen_US
dc.subjectBody-Compositionen_US
dc.subjectMuscleen_US
dc.subjectBoneen_US
dc.titleEvaluation of Sarcopenia with F-18 FDG PET/CT and relation with disease outcomes in patients with multiple myelomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu